IOL Chemicals & Pharmaceuticals Ltd

The transcript provided does not explicitly mention details regarding the current or expected order book or pending orders for IOL Chemicals and Pharmaceuticals Limited. However, some relevant points from the discussion related to business momentum and growth include: - The company reported revenue growth and strong capacity utilization (ibuprofen plant running over 90% capacity). - They expect to achieve revenue of around INR600 crores in Q4. - Focus on expanding products, increasing non-ibuprofen API share, and regulated market exports. - Capex plans of approximately INR150-200 crores aimed at growth and capacity expansion. - Ongoing R&D efforts and product pipeline expansion to strengthen future product offerings. - Emphasis on customer relationships and disciplined execution supporting sustained order flow. For specifics on the order book or pending orders, the transcript does not provide direct information. You may contact their IR team for detailed order book data.

- No explicit mention of any current or future fundraising through debt or equity was made during the call. - The company emphasized prudent financial management and a stable financial position supported by healthy operating cash flow. - Capex plans for FY '26 and FY '27 are in the range of INR 130-200 crores, which the company plans to fund through internal accruals. - There was no indication of plans to raise additional capital via equity or debt in the near term. - Management focuses on disciplined execution and cautious financial management to support growth without the need for external fundraising.

- FY '26 capex budget was around INR 150 crores; actual expected slightly lower (~INR 130-135 crores). - Approximately 60% of FY '26 capex directed towards growth, and 40% towards infrastructure development and automation. - For FY '27, the company plans a similar level of capex (~INR 150-200 crores), though final plans are yet to be finalized. - Capex aims to support increased capacity, particularly expanding key products like paracetamol and non-ibuprofen APIs. - New land acquisition is in process with environmental clearances secured; pending approvals with national highway authorities; intended for setting up additional plants. - Focus on enhancing capacity utilization and broadening product portfolio with ongoing R&D efforts for new molecules in API and chemical segments.

- The company expects a minimum 10% to 15% growth in top line (sales/revenue) in the coming year (FY '27). - Bottom-line growth is anticipated between 15% to 20%. - The focus is on increasing exports, especially of pharmaceutical products, including efforts to boost the non-ibuprofen (non-ibu) API share. - Capacity utilization is high for pharma (above 90%), except paracetamol which is expanding; chemicals utilization is near 200%. - The paracetamol segment is expected to be a key growth driver, alongside metformin and the shift of non-ibu domestic sales to regulated markets. - New capacities are being planned, with ongoing capex of around INR 150-200 crores annually. - The company is targeting a balanced product mix aiming for 60% revenue from API and 40% from chemicals in next 2 years, with growth driven by both ibuprofen and non-ibuprofen APIs. - Revenue guidance for Q4 is INR 600 crores with improved margins.

- Company expects 10% to 15% growth in top line for FY '27. - Bottom line projected to grow 15% to 20% in FY '27. - EBITDA margins anticipated to improve by 1% to 2% in coming quarters, targeting about 11%-12% in near term. - EBITDA margin upside of 10% to 15% possible over current margin profile in next year. - Revenue target for FY '27 is around INR 2,700 crores combining API and chemical businesses. - API business expected to constitute 60% and chemical business 40% of revenues in near term, evolving towards 75% API over 4-5 years. - Capacity utilization in pharma currently over 90%, chemicals near 200%, supporting volume-driven growth. - Ongoing capex of INR 150-200 crores planned for FY '27 to support expansion. - Growth driven by exports, non-ibuprofen segments, expansion in regulated markets, and volume optimization.